NCT05440799
Completed
Phase 1
Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1819479 in Healthy Female Subjects of Non-childbearing Potential (Double-blind, Randomised, Placebo-controlled, Parallel Group Design)
Overview
- Phase
- Phase 1
- Intervention
- BI 1819479
- Conditions
- Healthy
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 62
- Locations
- 1
- Primary Endpoint
- Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1819479 in healthy female subjects of non-childbearing potential.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy female subjects of non-childbearing potential according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests
- •Age between 18 years and 67 (inclusive)
- •Body mass index (BMI) of 18.5 to 30.9 (weight divided by height squared)(kg/m2) (inclusive)
- •Signed and dated written informed consent in accordance with International Conference on Harmonisation (ICH) - Good Clinical Practice (GCP) and local legislation prior to admission to the trial
- •Female subject of non-childbearing potential defined as:
- •Permanently surgically sterilised (hysterectomy, bilateral salpingectomy and/or bilateral oophorectomy)
- •Postmenopausal, defined as no menses for 1 year in women aged = 51 years or no menses for 2 years in women aged = 50 years, without an alternative medical cause
- •In questionable cases of postmenopausal status:
- •Women not using sex hormone medication such as hormone replacement therapy may be included if a blood sample confirms levels of Follicle-stimulating hormone (FSH) \> 40 unit/liter (U/L) and estradiol \< 30 nanogram per liter (ng/L)
- •Women using sex hormone medication such as hormone replacement therapy cannot be included in the trial
Exclusion Criteria
- •Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
- •Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetres of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm)
- •Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- •Any evidence of a concomitant disease assessed as clinically relevant by the investigator
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
- •Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
- •History of relevant orthostatic hypotension, fainting spells, or blackouts
- •Further exclusion criteria apply
Arms & Interventions
BI 1819479
Intervention: BI 1819479
Placebo
Intervention: BI matching placebo
Outcomes
Primary Outcomes
Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator
Time Frame: up to 106 days
Secondary Outcomes
- Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)(up to 92 days)
- Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)(up to 92 days)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles MidazolamHealthyNCT06327256Boehringer Ingelheim40
Completed
Phase 1
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 in Healthy Male VolunteersHealthyNCT01681277Boehringer Ingelheim48
Completed
Phase 1
A Study to Test How Different Doses of BI 765423 Are Taken up in the Body of Healthy MenHealthyNCT05658107Boehringer Ingelheim64
Completed
Phase 1
A Trial in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are ToleratedHealthyNCT04866160Boehringer Ingelheim24
Terminated
Phase 1
A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are ToleratedHealthyNCT03868540Boehringer Ingelheim24